临床路径应用于肺结核住院治疗中的效果评价

Effect Evaluation of Clinical Pathway on the Inpatient Treatment of Pulmonary Tuberculosis

目的评价临床路径在对于肺结核患者住院期间天数、好转率、死亡率、再住院率、住院费用、药费、检査费用、日均费用等方面的影响。方法将符合纳入标准的患者随机分为两组,对照组常规诊治,临床路径组按照肺结核临床路径诊治。比较两组患者在住院天数、好转率、死亡率、再住院率、住院费用、药费、检査费用、日均费用等方面的差异。结果初治菌阳肺结核患者及初治菌阴肺结核两组住院天数均有统计学差异(P<0.05);复治肺结核患者两组住院天数有显著差异(P<0.01)。初治菌阳肺结核再住院率有统计学差异(P<0.05)。临床路径组住院费用低于非临床路径组(P<0.05)。结论临床路径的实施可降低住院天数及住院费用,能减轻患者及国家经济负担,同时,临床路径的实施还可降低肺结核再住院率。

Objective To evaluate the impacts of clinical pathway in patients with pulmonary tuberculosis on hospitalization, days, improvement rate, mortality, rate of re - hospitalization, hospitalization expenses, drug cost, inspection cost, daily cost and other aspects. Method Patients were randomly divided into two groups, the control group conventional treatment, the clinical pathway group according to the clinical pathway treatment of pul- monary tuberculosis. The differences were compared between the two groups in the duration of hospitalization, re- covery rate, mortality, rate of hospitalization, hospitalization expenses, fees, inspection fees, daily expense. Re- sult Length of stay ： initial treatment of tuberculosis patients and the initial treatment of pulmonary tuberculosis a- mong two groups in hospitalization days were statistically （ P 〈 0.05 ） ; Hospital days of pulmonary tuberculosis pa- tients of two groups have significant difference （P 〈0.01 ）. The readmission rate： tuberculosis hospitalization rate was statistically difference （ P 〈 O. 05 ）. Cost ： clinical pathway group hospitalization costs lower than non - clinical pathway group （P 〈 0.05 ）. Conclusion The implementation of clinical pathway can reduce the hospitalization days and the hospitalization cost, can reduce the economic burden of patients and the state. At the same time, the implementation of clinical pathway can reduce the readmission rate of oulmonarv tuberculosis.